U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C43H58N4O12
Molecular Weight 822.9419
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of RIFAMPIN

SMILES

C[C@@]1([H])/C(/[H])=C(\[H])/C(/[H])=C(/C)\C(=Nc2c(/C(/[H])=N/N3CCN(C)CC3)c(c4c(c(c(C)c5c4C(=O)[C@@](C)(O/C(/[H])=C(\[H])/[C@@]([H])([C@@]([H])(C)[C@]([H])([C@]([H])(C)[C@@]([H])([C@]([H])(C)[C@@]1([H])O)O)OC(=O)C)OC)O5)O)c2O)O)O

InChI

InChIKey=JQXXHWHPUNPDRT-WLSIYKJHSA-N
InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1

HIDE SMILES / InChI

Molecular Formula C43H58N4O12
Molecular Weight 822.9419
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment:: http://www.wikidoc.org/index.php/Rifampin_(oral)

Rifampin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. It is FDA approved for the treatment of tuberculosis, meningococcal carrier state. Healthy subjects who received rifampin 600 mg once daily concomitantly with saquinavir 1000 mg/ritonavir 100 mg twice daily (ritonavir-boosted saquinavir) developed severe hepatocellular toxicity. Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. Common adverse reactions include heartburn, epigastric distress, anorexia, nausea, vomiting, jaundice, flatulence, cramps.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P0A8V2
Gene ID: 948488
Gene Symbol: rpoB
Target Organism: Escherichia coli (strain K12)
18.5 µM [Ki]
30.1999999999999993 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RIFADIN

Approved Use

In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. Tuberculosis Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER®) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin, and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive. RIFADIN IV is indicated for the initial treatment and retreatment of tuberculosis when the drug cannot be taken by mouth. Meningococcal Carriers Rifampin is indicated for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. Rifampin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms. (See WARNINGS.) Rifampin should not be used indiscriminately, and therefore, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed for establishment of the carrier state and the correct treatment. So that the usefulness of rifampin in the treatment of asymptomatic meningococcal carriers is preserved, the drug should be used only when the risk of meningococcal disease is high. To reduce the development of drug-resistant bacteria and maintain the effectiveness of rifampin and other antibacterial drugs, rifampin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

43632000000
Curative
RIFADIN

Approved Use

In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. Tuberculosis Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER®) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin, and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE®) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive. RIFADIN IV is indicated for the initial treatment and retreatment of tuberculosis when the drug cannot be taken by mouth. Meningococcal Carriers Rifampin is indicated for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. Rifampin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms. (See WARNINGS.) Rifampin should not be used indiscriminately, and therefore, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed for establishment of the carrier state and the correct treatment. So that the usefulness of rifampin in the treatment of asymptomatic meningococcal carriers is preserved, the drug should be used only when the risk of meningococcal disease is high. To reduce the development of drug-resistant bacteria and maintain the effectiveness of rifampin and other antibacterial drugs, rifampin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

43632000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
21.6 mg/L
20 mg/kg 1 times / day steady-state, oral
dose: 20 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
25.1 mg/L
25 mg/kg 1 times / day steady-state, oral
dose: 25 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
33.1 mg/L
30 mg/kg 1 times / day steady-state, oral
dose: 30 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
35.2 mg/L
35 mg/kg 1 times / day steady-state, oral
dose: 35 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.4 mg/L
10 mg/kg 1 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.3 mg/L
10 mg/kg 1 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6.3 mg/L
10 mg/kg 1 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
325 μg × h/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFAMPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
113 mg × h/L
20 mg/kg 1 times / day steady-state, oral
dose: 20 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
135 mg × h/L
25 mg/kg 1 times / day steady-state, oral
dose: 25 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
190 mg × h/L
30 mg/kg 1 times / day steady-state, oral
dose: 30 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
235 mg × h/L
35 mg/kg 1 times / day steady-state, oral
dose: 35 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
26.3 mg × h/L
10 mg/kg 1 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ISONIAZID
RIFAMPIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17.3 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
25-DESACETYLRIFAMPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
16.3 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFAMPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
60 g single, oral
Overdose
Dose: 60 g
Route: oral
Route: single
Dose: 60 g
Sources:
unknown, 26 years
Health Status: unknown
Age Group: 26 years
Sex: M
Sources:
Other AEs: Pruritus...
Other AEs:
Pruritus (grade 5, 1 patient)
Sources:
1200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
unknown, adult
Health Status: unknown
Age Group: adult
Sex: M
Sources:
AEs

AEs

AESignificanceDosePopulation
Pruritus grade 5, 1 patient
60 g single, oral
Overdose
Dose: 60 g
Route: oral
Route: single
Dose: 60 g
Sources:
unknown, 26 years
Health Status: unknown
Age Group: 26 years
Sex: M
Sources:
Overview

Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
yes [IC50 79.1 uM]
yes [Ki 18.5 uM]
yes [Ki 30.2 uM]
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: induced levels of CYP1C19 apoprotein to 330% of control; coadministration with simvastatin: decrease exposure of simvastatin; coadministration with irinotecan: decrease irinotecan and active metabolite exposure; rifampicin reduced AUC of repaglinide by 57%;
Page: 12
yes
yes (co-administration study)
Comment: Coadministration of ertugliflozin with rifampin decreased ertugliflozin AUC0-∞ and Cmax by 39% and 15%, respectively
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Letter: Acute renal failure caused by rifampicin].
1975 Apr 19
[A new case of acute renal failure, with high hemolysis, after rifampicin (author's transl)].
1975 Nov-Dec
[Tolerance of rifampicin in long-term treatment of patients with pulmonary tuberculosis].
1976 Feb
Rifampin-induced methadone withdrawal.
1976 May 13
Antibacterials for the prophylaxis and treatment of bacterial endocarditis in children.
2001
Bullous necrotizing fixed drug eruption with hepatitis due to rifampicin.
2001 Apr-Jun
Drug-induced acute interstitial nephritis.
2001 Aug
Postantibiotic effects of antituberculosis agents alone and in combination.
2001 Dec
[Acute kidney failure induced by rifampicin].
2001 Jan-Feb
[Clinico-pathological features and possible pathogenesis of rifampicin-induced acute renal failure].
2001 Jun
CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit.
2001 May
Rifampicin-induced lupus erythematosus.
2001 May
[Acute renal insufficiency and interstitial nephritis caused by rifampicin. A comment on this subject].
2001 May-Jun
Acute renal failure caused by rifampicin re-exposure with 10-year of interval.
2001 Nov
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Antimycobacterial plant terpenoids.
2001 Nov
[Post-rifampicin acute renal failure--serious, but seldom recognized complication of the anti-tuberculosis treatment].
2001 Oct-Dec
Acute renal failure complicating rifampicin therapy.
2001 Sep
Optic neuropathy after treatment with anti-tuberculous drugs in a subject with Leber's hereditary optic neuropathy mutation.
2001 Sep
Bactericidal activities of commonly used antiseptics against multidrug-resistant mycobacterium tuberculosis.
2002
Limitations in the use of rifampicin-gelatin grafts against virulent organisms.
2002 Apr
Simple fibroblast-based assay for screening of new antimicrobial drugs against Mycobacterium tuberculosis.
2002 Aug
Receptor-dependent regulation of the CYP3A4 gene.
2002 Dec 27
Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.
2002 Feb
In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum.
2002 Feb
Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex.
2002 Feb
Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression.
2002 Feb 28
Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis.
2002 Jan
Rapidly progressive glomerulonephritis due to rifampicin therapy.
2002 Jan
Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin.
2002 Jan
[Specific features of acute renal failure in patients treated with rifampicin].
2002 Jan-Mar
CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.
2002 Jul
Diffuse glomerulonephritis associated with rifampicin treatment for tuberculosis.
2002 Jun
Paraquat detoxicative system in the mouse liver postmitochondrial fraction.
2002 Jun 1
Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR.
2002 May
Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis.
2002 May
3-[4'-bromo-(1,1'-biphenyl)-4-yl]-N, N-dimethyl-3-(2-thienyl)-2-propen-1-amine: synthesis, cytotoxicity, and leishmanicidal, trypanocidal and antimycobacterial activities.
2002 Nov
PXR-dependent induction of human CYP3A4 gene expression by organochlorine pesticides.
2002 Nov 15
Acute renal failure due to rifampicin: a study of 25 patients.
2002 Oct
Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR).
2002 Oct 15
Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid.
2002 Oct 15
Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor.
2003 Apr
Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis.
2003 Apr
Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
2003 Apr
A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression.
2003 Apr 18
Molecular basis of rifampicin-induced inhibition of anti-CD95-induced apoptosis of peripheral blood T lymphocytes: the role of CD95 ligand and FLIPs.
2003 Jan
Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.
2003 Jan
Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices.
2003 Mar
Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes.
2003 May
Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products.
2003 May
Patents

Sample Use Guides

Tuberculosis: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, oral or intravenous. It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.
Route of Administration: Other
By the absolute concentration method, the MIC50 and MIC90 of rifampicin were 0.5-1 mg/L
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:55:05 UTC 2021
Edited
by admin
on Fri Jun 25 20:55:05 UTC 2021
Record UNII
VJT6J7R4TR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RIFAMPIN
HSDB   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
RIFALDAZINE
Common Name English
RIFAMPICIN [JAN]
Common Name English
BA-41166/E
Code English
RIMACTAN
Brand Name English
RIFATER COMPONENT RIFAMPIN
Common Name English
RIFAMPIN COMPONENT OF RIFATER
Common Name English
NSC-113926
Code English
RIFAMPICIN
EP   INN   MART.   WHO-DD   WHO-IP  
INN  
Official Name English
BA-41166E
Code English
RIMACTANE
Brand Name English
RIFADINE
Brand Name English
NIH-10782
Code English
RIFAMYCIN AMP
Common Name English
3-(((4-METHYL-1-PIPERAZINYL)IMINO)METHYL)RIFAMYCIN
Systematic Name English
RIFA
Brand Name English
RIFAMPICIN [IARC]
Common Name English
RIFAMPIN COMPONENT OF RIFAMATE
Common Name English
RIFAMPIN [MI]
Common Name English
RIFAMPICINUM [WHO-IP LATIN]
Common Name English
L-5103 LEPETIT
Code English
RIFAPRODIN
Brand Name English
RIFAMYCIN, 3-(((4-METHYL-1-PIPERAZINYL)IMINO)METHYL)-
Common Name English
RIFAMPICIN [MART.]
Common Name English
BA 41166/E
Code English
RIFOLDIN
Brand Name English
RIFAMPICIN [WHO-IP]
Common Name English
RIFAPIAM
Brand Name English
RIFAMPIN [USAN]
Common Name English
RIFAMYCIN AMP [MI]
Common Name English
L-5103
Code English
RIFAMPICIN [INN]
Common Name English
L-5103-LEPETIT
Code English
RIFAMATE COMPONENT RIFAMPIN
Common Name English
RIFAMPIN [ORANGE BOOK]
Common Name English
R/AMP
Common Name English
5,6,9,17,19,21-HEXAHYDROXY-23-METHOXY-2,4,12,16,18,20,22-HEPTAMETHYL-8-(N-(4-METHYL-1-PIPERAZINYL)FORMIMIDOYL)-2,7-(EPOXYPENTADECA(1,11,13)TRIENIMINO)NAPHTHO(2,1-B)FURAN-1,11(2H)-DIONE 21-ACETATE
Systematic Name English
ABRIFAM
Brand Name English
RIFAMPICIN [EP]
Common Name English
EREMFAT
Brand Name English
RIFADIN
Brand Name English
RIFAMPIN [USP MONOGRAPH]
Common Name English
RIFAMPICIN [EP MONOGRAPH]
Common Name English
RIFAMPIN [HSDB]
Common Name English
RIFALDIN
Brand Name English
RIFAMPIN [VANDF]
Common Name English
RIFAMPICIN [WHO-DD]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 6585
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ETH/ISO/PYR/RIF)
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
NDF-RT N0000175500
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ISO/RIF)
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ISO/PYR/RIF)
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
FDA ORPHAN DRUG 7685
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.3
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
NDF-RT N0000007911
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
NDF-RT N0000007911
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-VATC QJ04AM05
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-ATC J04AB02
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-ATC J04AM07
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-ATC J04AM02
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-ATC J04AM05
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
NCI_THESAURUS C280
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-VATC QJ04AB02
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
NDF-RT N0000007911
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.4
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-VATC QJ04AM02
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-ATC J04AM06
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ETH/ISO/RIF)
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-VATC QJ04AM06
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
NDF-RT N0000007911
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
NCI_THESAURUS C25995
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
WHO-VATC QJ54AB02
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
LIVERTOX 845
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL374478
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
WIKIPEDIA
RIFAMPICIN
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
RIFAMPIN
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY Description: A brick red to red-brown, crystalline powder. Solubility: Very slightly to slightly soluble in water; soluble in methanol R; slightly soluble in acetone R, ethanol (~750 g/l) TS, and ether R. Category: Antileprosy drug; antituberculosis drug. Storage: Rifampicin should be kept in a tightly closed container or in an atmosphere of nitrogen, protected from light. Additional information: Rifampicin exhibits polymorphism. Definition: Rifampicin contains not less than 97.0% and not more than 102.0% of C43H58N4O12, calculated with reference to the dried substance.
EPA CompTox
13292-46-1
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
RXCUI
9384
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY RxNorm
INN
2323
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
HSDB
3181
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
PUBCHEM
135398735
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
LACTMED
Rifampin
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
USP_CATALOG
1604009
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY USP-RS
CAS
845504-52-1
Created by admin on Fri Jun 25 20:55:05 UTC 2021 , Edited by admin on Fri Jun 25 20:55:05 UTC 2021
ALTERNATIVE
MESH
D012293
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
IUPHAR
2765
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
ECHA (EC/EINECS)
236-312-0
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
NCI_THESAURUS
C811
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
EVMPD
SUB10309MIG
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
MERCK INDEX
M9611
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY Merck Index
DRUG CENTRAL
2377
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
DRUG BANK
DB01045
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
CAS
13292-46-1
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
FDA UNII
VJT6J7R4TR
Created by admin on Fri Jun 25 20:55:06 UTC 2021 , Edited by admin on Fri Jun 25 20:55:06 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INDUCER
POTENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INDUCER
TRANSPORTER -> INDUCER
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> INDUCER
TRANSPORTER -> INHIBITOR
SUBSTRATE USED: Bromsulphthalein (BSP)
METABOLIC ENZYME -> INDUCER
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INDUCER
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INDUCER
POTENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
CAN BE USED FOR IN-VIVO STUDIES OF TRANSPORTER
IN-VIVO
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
METABOLIC ENZYME -> INDUCER
Related Record Type Details
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Duration of Action PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

MIC BIOLOGICAL SUSCEPTIBILITY: RESISTANT

PATHOGEN: N. MENINGIDITIS

Biological Half-life PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC POPULATION: END-STAGE RENAL DISEASE

Tmax PHARMACOKINETIC POPULATION: PEDIATRICS

ROUTE OF ADMINISTRATION: ORAL

Cmax PHARMACOKINETIC POPULATION: PEDIATRICS

ROUTE OF ADMINISTRATION: ORAL

Biological Half-life PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

POPULATION: PEDIATRICS

Biological Half-life PHARMACOKINETIC POPULATION: HEPATIC IMPAIRMENT

Biological Half-life PHARMACOKINETIC ROUTE OF ADMINISTRATION: IV

POPULATION: PEDIATRICS

Cmax PHARMACOKINETIC POPULATION: PEDIATRICS

ROUTE OF ADMINISTRATION: IV

MIC BIOLOGICAL PATHOGEN: N. MENINGIDITIS

SUSCEPTIBILITY: SUSCEPTIBLE

Tmax PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

MIC BIOLOGICAL PATHOGEN: N. MENINGIDITIS

SUSCEPTIBILITY: INTERMEDIATE